HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Donna McEachern Selected Research

SM 164

3/2012LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.
5/2011Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
4/2011Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.
11/2008SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Donna McEachern Research Topics

Disease

30Neoplasms (Cancer)
10/2021 - 03/2008
10Leukemia
01/2021 - 10/2014
8Breast Neoplasms (Breast Cancer)
10/2020 - 05/2011
3Prostatic Neoplasms (Prostate Cancer)
01/2021 - 10/2014
3Colonic Neoplasms (Colon Cancer)
10/2014 - 06/2008
3Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2014 - 10/2012
2Osteosarcoma (Osteogenic Sarcoma)
01/2015 - 10/2014
1Lymphoma (Lymphomas)
01/2020
1Triple Negative Breast Neoplasms
01/2017
1Ovarian Neoplasms (Ovarian Cancer)
03/2012
1Head and Neck Neoplasms (Head and Neck Cancer)
04/2011
1Squamous Cell Carcinoma of Head and Neck
04/2011

Drug/Important Bio-Agent (IBA)

18Proteins (Proteins, Gene)FDA Link
01/2021 - 04/2011
5Inhibitor of Apoptosis ProteinsIBA
09/2013 - 11/2008
4snake venom protein C activatorIBA
01/2021 - 08/2018
4SAR405838IBA
12/2016 - 10/2014
4SM 164IBA
03/2012 - 11/2008
3STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
06/2021 - 11/2019
3Proteolysis Targeting ChimeraIBA
01/2021 - 08/2018
3Androgen Receptors (Androgen Receptor)IBA
01/2021 - 10/2020
2enzalutamideIBA
01/2021 - 10/2020
2indoleIBA
01/2018 - 11/2017
2Pharmaceutical PreparationsIBA
06/2015 - 03/2012
2Oncogene Proteins (Oncogene Protein)IBA
10/2014 - 06/2008
2N- benzhydryl- 5- (2- (methylamino)propanamido)- 3- (3- methylbutanoyl)- 6- oxodecahydropyrrolo(1,2- a)(1,5)diazocine- 8- carboxamideIBA
09/2013 - 04/2011
1Cysteine (L-Cysteine)FDA Link
01/2021
1Anaplastic Lymphoma KinaseIBA
11/2020
1ARD-61IBA
10/2020
1Transcription Factors (Transcription Factor)IBA
12/2019
1Proto-Oncogene Proteins c-mdm2IBA
01/2019
1pyrazoleIBA
01/2018
1quinolineIBA
11/2017
1Estrogen ReceptorsIBA
12/2016
1Estradiol (Delestrogen)FDA LinkGeneric
12/2016
1Fulvestrant (Faslodex)FDA Link
12/2016
1ABT-737IBA
06/2015
1navitoclaxIBA
06/2015
1BM-1197IBA
01/2014
1Caspase 8 (Caspase-8)IBA
09/2013
1Biomarkers (Surrogate Marker)IBA
09/2013
1compound 30IBA
10/2012
1BM-957IBA
10/2012
1GSK 1363089IBA
03/2012
1Tyrosine Kinase InhibitorsIBA
03/2012
1Membrane Proteins (Integral Membrane Proteins)IBA
03/2012
1CrizotinibIBA
03/2012
1Phosphotransferases (Kinase)IBA
03/2012
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
03/2012
1tyrosine receptor (receptor, tyrosine)IBA
03/2012
1Radiation-Sensitizing AgentsIBA
04/2011
1CaspasesIBA
04/2011
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2008
12-oxindole (oxindole)IBA
06/2008
1MI-219IBA
03/2008

Therapy/Procedure

6Therapeutics
01/2021 - 09/2013
5Oral Administration
10/2021 - 07/2013
1Transplantation
09/2013